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Chimeric papillomavirus (PV) virus-like particles (VLPs) based on the bovine papillomavirus type 1 (BPV-1) L1 protein were
constructed by replacing the 23-carboxyl-terminal amino acids of the BPV1 major protein L1 with an artificial “polytope”
minigene, containing known CTL epitopes of human PV16 E7 protein, HIV IIIB gp120 P18, Nef, and reverse transcriptase (RT)
proteins, and an HPV16 E7 linear B epitope. The CTL epitopes were restricted by three different MHC class I alleles (H-2b,
H-2d, HLA-A*0201). The chimeric L1 protein assembled into VLPs when expressed in SF-9 cells by recombinant baculovirus.
After immunization of mice with polytope VLPs in the absence of adjuvant, serum antibodies were detected which reacted
with both polytope VLPs and wild-type BPV1L1 VLPs, in addition to the HPV16E7 linear B cell epitope. CTL precursors specific
for the HPV16 E7, HIV P18, and RT CTL epitopes were also detected in the spleen of immunized mice. Polytope VLPs can thus
deliver multiple B and T epitopes as immunogens to the MHC class I and class II pathways, extending the utility of VLPs as
self-adjuvanting immunogen delivery systems. © 2000 Academic Press
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Cytotoxic T lymphocytes (CTL) play a key role in erad-
ication of some infectious diseases and cancer by the
immune system (Byrne et al., 1984; McMichael et al.,
1983; Feltkamp et al., 1995). Novel vaccines capable of
inducing protective CTL responses have used recombi-
nant protein expressed in the experimental animals us-
ing viral (Perkus et al., 1995) or bacterial vectors (Shen et
al., 1995) or nucleic acids (Yang et al., 1995). Induction of
a broad response directed simultaneously against mul-
tiple CTL epitopes spread over multiple antigenic pro-
teins may be necessary for the development of success-
ful vaccines against many viral diseases, where immune
selection pressure may produce viral escape mutants.
An alternative strategy for CTL induction has been the
use of mixtures of synthetic peptide epitopes formulated
in appropriate adjuvants (Scalzo et al., 1995; Vitiello et al.,
1995). To enable the induction of multiple immune re-
sponses, this approach has been extended to include
various combinations of epitopes synthesized or ex-
pressed as a single defined nucleic acid or protein (An
and Whitton et al., 1997; Thomson et al., 1996, 1998;
Rodriguez et al., 1998; Hanke et al., 1998; Mateo et al.,
1999; Woodberry et al., 1999). However, such constructs
still require experimental adjuvants for the successful
induction of immune responses, and the ability of these
adjuvants to induce sustained CTL responses is not yet
established.
Papillomavirus (PV) major capsid protein L1, alone or
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374with the minor capsid protein L2, can self-assemble into
virus-like particles (VLPs) when expressed in eukaryotic
and prokaryotic systems (Zhou et al., 1991b; Roden et al.,
1996). These VLPs are highly immunogenic with or with-
out adjuvant and elicit high titers of systemic neutralizing
antibodies, which provide protection from experimental
challenge with infectious virus in animal papillomavirus
models (Christensen et al., 1996; Kirnbauer et al., 1996;
Lowe et al., 1997). C-terminal truncation mutants of PV L1
protein also form VLPs (Paintsil et al., 1996), and up to 60
amino acids can be added to this region of L1 without
disrupting the assembly of VLPs (Mu¨ller et al., 1997).
Thus, when an H-2Db restricted HPV16 E7 CTL epitope
aa318–327) (Feltkamp et al., 1993) or an H-2Dd restricted
IV P18 CLT epitope was added to the C-terminus of
ovine papillomavirus type 1 (BPV1) L1, the recombinant
f BPV1 L1 proteins self-assembled into VLPs which
licit immunity to PV and also to the incorporated CTL
pitopes (Peng et al., 1998).
We therefore made a chimeric BPV-1 L1 protein incor-
orating multiple foreign B and T cell epitopes to inves-
igate whether it was possible to use the self-adjuvanting
roperties of the papillomavirus VLP delivery system to
nduce multiple immune responses using a single de-
ined particle immunogen.
RESULTS
roduction of chimeric BPV1L1 polytope VLPs
A recombinant baculovirus expression system was
hosen to express a BPV1L1 polytope fusion protein.
his contained three HIV IIIB and one HPV CTL epitopes
n addition to a single HPV16 E7 antibody epitope in a
L
s
e
f
375VLPs TO DELIVER MULTIPLE CYTOTOXIC T CELL EPITOPES48-amino-acid sequence (Table 1) that was substituted
for the 23 C-terminal amino acids of the natural BPV-1 L1
sequence (Fig. 1). Deletion of the 23 most C-terminal
amino acids of BPV1 L1 does not interfere with L1 self-
assembly into VLPs (Paintsil et al., 1996), and a hybrid
HPV16 L1 fusion protein in which 60 foreign amino acids
are substituted for the C-terminal 23 amino acids of
HPV16 L1 can form VLPs (Mu¨ller et al., 1997). The BPV1
L1 polytope protein was expressed in Sf9 cells using
recombinant baculovirus, and VLPs were purified from
cell lysate by density gradient in the usual manner. Frac-
tions of the gradient were subjected to SDS–PAGE and a
band of around 60-kDa size was visible by Coomassie
blue staining of a fraction of density 1.30 g/ml. Compared
with wild-type BPV1L1, the apparent molecular weight of
the hybrid BPV1L1 was higher, as expected. The identity
of this band as an L1 fusion protein was confirmed by
immunoblot using L1-specific monoclonal antibodies
(Fig. 2). Electron microscope analysis of the gradient
fraction containing L1 showed virus-like particles of het-
erogeneous size, with some loss of icosahedral structure
when compared with the wild-type BPV1L1 VLPs (Fig. 3).
The BPV-1 L1 polytope protein formed VLPs from L1
protein with three- to fivefold lower efficiency, when com-
pared with the wild-type BPV1L1 as judged by the yield of
L1 protein in VLPs when compared with total L1 protein
expressed in rBV-infected cells (data not shown).
Antibody response to polytope VLPs
To test the ability of polytope BPV1L1 VLPs to induce
anti-BPV1L1 antibody, groups of BALB/c, C57BL/6, and
HLA-A2.1Kb transgenic mice were immunized twice with
FIG. 1. Construction of PVLBPV1L1 polytope transfer vector. The BPV
1 gene, truncated after the codon for residue 472, was extended by
equential PCR with overlapping primers to include DNA encoding the
ntire polytope sequence as shown. This chimeric L1 construct,
lanked by BamHI and EcoRI sites, was cloned into a baculovirus
intermediate vector pVL1393 at these sites.20 mg BPV1L1 polytope VLPs. Anti-BPVL1 VLP antibodies
were measured by capture ELISA, which is relativelyspecific for conformational antibody to VLPs. All immu-
nized mice produced antibodies that recognized both
polytope and native BPV1L1 VLPs. The titer of antibody
recognizing wt BPV1L1 VLPs was lower than that against
polytope VLPs (Fig. 4). In contrast, antiserum raised us-
ing WT-BPV1L1 VLPs recognized BPV1L1 VLPs better
than polytope VLPs (Fig. 4). These data suggest that the
dominant B epitopes of the polytope BPV1L1 VLPs were
different from those of the WT BPV1L1 VLPs. This obser-
vation, taken together with the EM appearance of the
particles and the immunogenicity data, suggests that
foreign antigens fused to the BPV1L1 C-terminus could
have a significant impact on the integrity of the L1 VLPs.
Sera from mice immunized with polytope VLPs were
also tested in ELISA using the incorporated E7 B epitope
as substrate. Peptide-specific antibody was measured in
both C57BL/6 and BALB/c mice, and only very low E7
antibody was measured in HLA-A2.1/Kb transgenic mice.
The titer of E7 peptide-specific antibody was quite low
compared to that of specific anti-L1 antibody (Fig. 5)
suggesting that the E7 B cell epitope, which is a strong
epitope when E7 is the immunogen, is subdominant to
conformational VLP B epitopes when contained in a
chimeric VLP.
In vivo induction of CTL responses by polytope VLPs
Polytope BPV1L1 VLPs carried four CTL epitopes re-
stricted by three different MHC alleles (Table 1). To
evaluate the ability of the polytope VLPs to prime CTL
responses in vivo to each of the CTL epitopes, C57BL/6
(H-2b) mice, BALB/C (H-2Kd), and HLA-A2.1.Kb transgenic
mice were immunized with purified BPV1L1 polytope
VLPs in PBS, with PBS only, or with denatured VLPs as
control. Splenocytes harvested 6 days after the second
immunization were restimulated with synthetic peptides
FIG. 2. Immunoblot detection of polytope VLPs protein. CsCl gradi-
ent-purified wild-type BPV1L1 VLPs, polytope VLPs, and wild-type bac-
ulovirus were separated by SDS–PAGE, blotted onto nitrocellulose
membrane and probed with MAb MC15, and reactivity was detected by
enhanced chemiluminescence. Protein markers are shown on the right.
Lane 1, BPV1L1 VLPs. Lanes 2 and 3, polytope VLPs. Lane 4, wild-type
baculovirus.
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376 LIU ET AL.corresponding to the recall epitopes in vitro to generate
bulk effector CTL, which were then used in standard
chromium-release assays against peptide-sensitized
or transfected tumor targets. The bulk effector CTL
from the C57BL/6 mice specifically lysed HPV16 E7
peptide-coated EL4 and E7 transfected tumor target
cells (C2) (Fig. 6), but did not lyse EL-4 cells in the
absence of E7 peptide, confirming the specificity of the
CTL responses. The bulk effector CTL from the BALB/c
mice similarly lysed HIV P18 peptide-coated P815
cells. The bulk effector CTL from HLA-A2.1/Kb trans-
FIG. 3. Electron microscopy of purified wild-type BPV1L1 VLPs. (A) B
each case.
FIG. 4. Antibody responses induced in three mouse strains by immu
LPs without adjuvant (VLP). Left: Specific antibody induced by polytope
y a capture ELISA against intact BPV1L1 polytope VLPs (squares) or w
LPs against polytope VLPs (squares) or VLPs (triangles) is shown for Balb/c
epresents data from pooled sera from a group of five mice.enic mice recognized HIV RT-polymerase peptide-
oated EL4S3-HHD cells, but did not recognize Nef
eptide-coated target cells. For this peptide immuno-
en, the peptide sequence used in the CTL assay
iffered by one amino acid residue from that incorpo-
ated in the polytope construct (Table 1). To confirm
hat the immunogenicity of the polytope VLPs was
ependent on their VLP conformation, mice were im-
unized with native configuration, denatured polytope
LPs, or PBS, and no CTL response was observed in
ice so immunized (data not shown).
VLPs. (B) Hybrid BPV1L1 polytope VLPs. The bar represents 100 nm in
n with BPV1L1 polytope VLPs without adjuvant (Poly VLP) or by BPV-1
filled symbols) and VLPs (open symbols) in C57Bl/6 mice was detected
BPV1L1 VLPs (triangles). Right: specific antibody induced by polytopenizatio
VLPs (
ild-type
(open symbols) or A2.1/Kb transgenic mice (filled symbols). Each point
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377VLPs TO DELIVER MULTIPLE CYTOTOXIC T CELL EPITOPESDISCUSSION
VLPs are candidate antigen delivery systems for the
nduction of neutralizing antibodies and of CTL epitopes
hrough the MHC class I presentation pathway. The cur-
ent results demonstrate the feasibility of delivering mul-
iple CTL epitopes in a single VLP construct to induce
esponses against many epitopes across individuals
ith diverse MHC backgrounds.
FIG. 5. Antibody responses against E7 peptide induced in three
mouse strains by immunization with BPV1 L1 polytope VLPs without
adjuvant. Specific antibody was detected by a peptide ELISA against
E7 antibody epitope. Negative control is sera from mice immunized
with PBS only. Each point represents data from pooled sera from a
group of five mice.
FIG. 6. Lysis of target cells presenting four different epitopes by splen
ALB/c (H-2Dd), C57BL/6 (H-2Db), and HLA-A.21Kb transgenic mice, im
51eptide. The generated effector cells were used in standard Cr-release a
dditionally against the C2 cell line expressing endogenous E7.CTL responses have been shown to play a critical role
n the elimination of virus infection or clearance of tumor,
o that an effective vaccine against viral infection might
equire incorporation of many different CTL specificities
o ensure protection against multiple viruses on a heter-
geneous collection of MHC backgrounds. CTL epitope-
ased plasmids encoding MHC class I, class II, and
ntibody-binding epitopes, delivered by immunizing with
ecombinant DNA or by infecting with recombinant vi-
uses, have been shown to be immunogenic in mice and
o confer protection against viral infection and cancer (An
nd Whitton, 1997; Gilbert et al., 1997; Thomson et al.,
996, 1998; Rodriguez et al., 1998; Hanke et al., 1998;
uhrbier, 1997), but hazards related to the nature of the
elivery systems may limit their usefulness as human
accines. Peptides, comprising multiple CTL epitopes
onjoined in a single, artificial construct, have been for-
ulated in various adjuvants which target the MHC class
pathway and lead to the generation of CTL responses
Vitiello et al., 1995). VLPs can mimic the immunological
unction of a virus, but are not infectious and, conse-
uently, have been trialled as vaccines. Recombinant Ty-
LPs carry a string of up 15 defined CTL epitopes from
lasmodium species prime protective CTL responses in
ice following a single administration without adjuvant
from murine BPV1L1 polytope VLP vaccinated mice. Splenocytes from
ed with polytope VLPs, were stimulated in vitro with the appropriateocytes
munizssays against peptide-coated or uncoated target cells and, for E7,
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378 LIU ET AL.(Gilbert et al., 1997). VLPs apparently possess an inher-
nt adjuvant activity which allows for effective MHC
lass I-restricted presentation of CTL epitopes. This is
ikely due their particulate nature and to the expression
f a6 integrin, the putative PV receptor (Evander et al.,
997), on dendritic cells (Al Jabbir, submitted).
Several antigen delivery systems based on VLPs in-
uce CTL activity. Hybrid HIV gag particles induce a
trong anti-V3 loop CTL response (Griffiths et al., 1993).
himeric hepatitis B surface antigen particles containing
IV-1 determinants or HPV16 E7 determinants stimulate
pecific CTL responses (Michel et al., 1993; Tindle et al.,
1994). Recombinant parvovirus-like particles harboring a
CTL epitope from lymphocytic virus (LCMV) nucleopro-
tein induce complete protection of mice against a nor-
mally lethal LCMV infection (Sedlik et al., 1997). PV VLPs
are highly immunogenic when administered to mice,
primates, and humans (Zhang et al., 2000; Nardelli-
Haefliger et al., 1999; Lowe et al., 1997), suggesting that
chimeric VLPs might act as effective “dual-purpose” vac-
cines for inducing neutralizing antibodies which prevent
infection and CTLs that eradicate established infections.
The papillomavirus major protein, L1, has a carboxyl-
terminus that encodes a nuclear localization signal but
otherwise shows relatively low sequence homology be-
tween different PV types (Zhou et al., 1991a). Deletion of
part of the BPV1L1 C-terminal sequence does not inter-
fere with L1 self-assembly into VLPs and, in contrast, the
yield is increased by an unknown mechanism (Paintsil et
al., 1996). Efficient formation of VLPs was obtained with a
recombinant construct in which the carboxy-terminal 34
amino acids of HVP16 L1 were replaced by up to 60
amino acids, and this modification did not interfere with
basic structural and functional properties of the particles
(Mu¨ller et al., 1997). The carboxyl terminus 23 amino
acids of bovine papillomavirus type-1 L1 protein is not
required for capsid formation, and it can be replaced by
at least some inserted sequence without decreased VLP
formation. Bovine papillomavirus L1 VLPs containing de-
fined CTL epitopes including HIV P18 CTL epitope or
HPV16 E7 CTL epitope were able to induce CTL re-
sponses through the MHC class I pathway (Peng et al.,
1998), and the resulting response could inhibit growth of
an E7 tumor cell line in vivo. Chimeric human papilloma-
virus type 16 L1 VLPs containing the first 60 amino acids
of HPV16 E7 protein could induce E7-specific CTLs and
protected mice from tumor growth and induced regres-
sion of tumors in vivo (Scha¨ffer et al., 1999). HPV16 L1
VLPs incorporating an HPV16 L2- E7 fusion protein could
protect immunized mice from challenge with a tumor-
expressing cell line expressing E7, although E7-specific
CTL were not demonstrated (Greenstone et al., 1998). All
of these data indicated that chimeric papillomavirus
VLPs are useful delivery systems for tumor immunother-
apy. Given that up to 60 amino acids can be fused to the
carboxy-terminus of L1 without affecting VLP assembly,
c
nwe wished to determine whether we could incorporate
more than one CTL epitope into the chimeric particle to
circumvent the problem of MHC polymorphism in out-
bred populations. We hypothesized that these particles
would be able to induce a CTL response against each
added epitope in addition to the L1 portion. In our study,
three of four CTL epitopes in the polytope VLP constructs
were clearly capable of inducing a MHC-I-restricted CTL
response in the appropriate mouse strain in the absence
of adjuvants. In our system, replacement of 23 amino
acids of the BPV1L1 C-terminus with a minigene encod-
ing 48 amino acids markedly decreased the formation of
VLPs and caused significant morphology changes when
compared with the wild-type BPVL1 VLPs. In contrast,
insertion of the entire GFP gene (encoding 237 amino
acids) to the C-terminus of BPV1L1 permitted the forma-
tion of normal size and fluorescent VLPs, but the yield
was extremely reduced (our unpublished observations),
whereas 30 amino acids of the influenza matrix protein,
when fused to the C-terminus of HPV16 L1, produced
only small numbers of intact VLPs (Mu¨ller et al., 1997).
Modifications the C-terminus of L1 thus do not always
result in stable PV VLP formation, and stability depends
not only on the length of insert but also on the nature of
the inserted gene.
Chimeric VLPs have been demonstrated in a hemag-
glutination assay (Roden et al., 1995) to induce antibod-
ies to conformational epitopes of PV, as are required for
virus neutralization in CRPV challenge systems, after
immunization with or without adjuvant (Mu¨ller et al., 1997;
Liu et al., 1998; Peng et al., 1998). Several studies have
hown that VLPs and chimeric VLPs can bind to and
enetrate cells in a manner similar to that of infectious
irions (Mu¨ller et al., 1997; Muller et al., 1995; Zhou et al.,
995) and suggest that modification of the native VLP by
he insertion of a foreign gene does not interfere with this
unction of VLPs. However, in our study, the serum from
ll three strains of mice immunized with polytope chi-
eric VLPs reacted with polytope VLPs better than WT-
ype BPV1L1 VLPs. In contrast, the serum from wild-type
PV1L1 immunized mice gave greater reactivity against
PV1L1 VLPs than against polytope VLPs. Together with
orphological data, this observation allows the conclu-
ion that structural and functional properties of our poly-
ope VLPs are altered by the inclusion of a foreign gene
t the C-terminus.
This study also addressed whether CTL epitopes
ight be delivered together with sequences containing B
ell epitopes other than L1. Although the HPV16 E7 B cell
pitope included in the chimeric VLPs was highly immu-
ogenic as a peptide coupled with GST (Fernando et al.,
998), a range of mice immunized with polytope VLPs
roduced only low levels of E7 antibody to this epitope.
urthermore, chimeric VLPs did not react with E7-spe-
ific antibodies when examined by capture ELISA (data
ot shown). These observations are in agreement with
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379VLPs TO DELIVER MULTIPLE CYTOTOXIC T CELL EPITOPESthe proposed partial or complete internal localization of
the inserted sequences within the chimeric VLPs (Mu¨ller
et al., 1997).
Both HPV and HIV are sexually transmitted viral dis-
eases and are currently the focus of numerous vaccine
studies. The present study has coupled the papillomavi-
rus L1 VLPs with HPV16 E7, HIV gp160, RT-polymerase,
and nef protein CTL epitopes. The strong CTL response
against HPV16 E7, HIV P18, and RT-polymerase induced
by polytope BPV1L1 VLPs suggests that it is possible to
design a VLP-based vaccine against more than one
sexually transmitted virus. The present study has dem-
onstrated that hybrid PV VLPs can be used as an efficient
antigen delivery system to deliver more than one CTL
epitope through MHC class I pathways, although we
have not tested for two discrete CTL responses in the
same animal. The length and site of optimal foreign
protein incorporated into the L1 VLPs and the stability of
the resulting chimeric VLPs may, however, require em-
piric definition if polytope VLPs are to be considered an
immunization strategy for controlling several viral infec-
tions on several MHC backgrounds using a single im-
munization.
MATERIALS AND METHODS
Mice, cell lines, and peptides
Adult female C57BL/6J, BALB/c, and HLA-A2.1/Kb
transgenic (H-2b) mice were purchased from the Animal
Resource Center (Australia). The HPV 16 E7 transfected
EL4 cell line C2 (Tindle et al., 1995), the parent line EL4,
and the P815 cell line were maintained in complete RPMI
1640 medium plus 10% fetal bovine serum (FBS, CSL,
Australia). The HLA-A2.1/Kb transfected EL4 cell line,
L4S3-HHD, was obtained from Dr. Andreas Suhrbier
nd was maintained in complete RPMI medium contain-
ng 10% FBS plus 400 mg/ml G418. Peptides synthesized
using F-moc chemistry were purchased from Chiron
(Melbourne, Australia).
Construction of recombinant baculovirus transfer
vectors
The following three primers, designed to fuse the poly-
tope gene to the C-terminus of BPV1L1 sequence, delet-
ing nucleotides from 7625 downstream, were purchased
from Life Technology.
Primer A: 59-ATTGTAACAAATGCTCTCCCTGGTCCTC-
TCTGGATACGAAAGGTTACAATATTGTAATGGGCTCTGT-
CCGGTTCTGCTTGTGCTCCTGCCCCTTGCTGTGCTA-39;
Primer B: 59-CGGAATTCTTATTTCAAATCATCCATGTA-
TTGGTAGATAACTAGCTTGAAGCACCACCCAAAGGTC-
AGGGGTTTTCCTATTGTAACAAATGCTCTCCC-39;Primer C: 59-CCGGGATCCATGGCGTTGTGGCAACAA-
GGCCAGAAGC-39.
h
ePrimer A and primer B represent a 144-bp insert se-
quence. The nucleic acid sequence of the fusion coded
for one flanking EcoRI restriction site, a stop codon, and
four CTL epitopes restricted by three MHC alleles and a
B cell epitope from HPV16 E7 (Table 1). The primer C
coded for one flanking BamHI restriction site. Initially
primer A, primer C, and the BPV1L1 gene were used to
fuse DNA encoding the first 27 amino acids of the poly-
tope construct to BPV1L1. Similarly, primer B and primer
C and the first PCR product were used to extend this
intermediate construct to form the complete hybrid
BPV1L1 gene. The PCR products were digested with
BamHI and EcoRI and inserted into a baculovirus trans-
fer vector, pVL1393 (Pharmingen), at the BamHI and
EcoRI sites. The ligation product was used to transform
Escherichia coli DH a-5 cells. The correct recombinant
clones were confirmed by the existence of BamHI and
EcoRI sites and also sequenced by dideoxynucleotide
procedures to determine the orientation and integrity of
the inserted sequences.
Construction of recombinant baculovirus
Spodoptera frugiperda (Sf9) cells were grown at 28°C
as suspension or monolayer cultures in TNMFH medium
(Sigma) supplemented with 10% FBS, 2 mM glutamine.
For recombinant baculovirus construction, 10 mg plasmid
was used to transfect Sf9 cells together with 2 mg of
linearized Baculo-Gold DNA (Pharmingen, San Diego,
CA). Recombinant viruses were purified by standard
methods as suggested by the manufacturer. To test for
the expression of BPV1L1 capsid protein, 106 Sf9 cells
ere infected with baculovirus recombinants at an m.o.i.
f 5 to 10. After incubation, medium was removed and the
ells were washed with PBS. The cells were then lysed
n SDS–sample buffer and analyzed by SDS–PAGE and
mmune blotting assay.
roduction and purification of VLPs
The production and purification procedures for VLPs
TABLE 1
Epitopes Included in the Polytope VLPs
Epitope description Amino acid sequence Restriction
PV16E7 B epitopes QAEPD
PV16E7 CTL epitope RAHYNIVTF H-2 Db
HIV gp120 P18 CTL epitope RIQRGPGRAFVTIGK H-2 Dd
HIV RT CTL epitope VIYQYMDDL HLA-A2.1
HIV Nef CTL epitope PLTFGWCYKLa HLA-A2.1
a The predicted sequence encoded by the polytope PLTFGWCFKL
iffers at residue 8 from the naturally occurring epitope used as target
or the CTL responses.ave previously been described (Qi et al., 1996). In gen-
ral, Sf-9 insect cells were infected with recombinant
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380 LIU ET AL.baculovirus at an m.o.i. of 10 per cell and incubated at
28°C for 72 h. The cells were centrifuged, washed once
with PBS, and resuspended in an appropriate amount of
PBS in the presence of 2 mM PMSF. The cell suspension
was homogenized with a Dounce homogenizer and then
centrifuged at 3000 rpm for 10 min at 4°C to separate the
nuclear fraction. The pellet was resuspended in an ap-
propriate resuspension buffer and sonicated for 45 s on
ice. The nucleus suspension was then loaded onto a 20%
sucrose cushion and centrifuged at 26,000 rpm in a
Beckman SW-26 rotor at 4°C for 2 h. The pellets were
resuspended with resuspension buffer and sonicated
again for another 45 s. This resuspension was then
mixed with CsCl and centrifuged at 20°C with a Beck-
man SW-41 rotor for 20 h. A band with a density of 1.28
g/ml was collected and dialyzed extensively against PBS.
Immunoblot analysis
Protein samples were diluted in SDS–PAGE sample
buffer, boiled at 100°C for 10 min, and electrophoresed
through a 10% SDS–PAGE gel and then transferred to a
nitrocellulose membrane. The membrane was blocked
with 5% skim milk in PBS and probed with the anti-L1
monoclonal antibody MC15 (Kulski et al., 1998) at a
dilution of 1:2000. Bound antibody was detected by in-
cubation of the membrane with horseradish-peroxidase-
conjugated sheep anti-mouse antibody (Silenus, Austra-
lia) at a dilution of 1:1000 and visualized using enhanced
chemiluminescence (Amersham).
Transmission electron microscopy
Samples of the VLP fractions from the CsCl gradients
were dialyzed against 10 mM HEPES (pH 7.5) for 45 min
on floating filter pads (0.02-mm pore size, Millipore).
Carbon-coated copper grids (200-mesh size; EM Sci-
ences) were treated with 20 ml of poly-L-lysine (1 mg/ml;
igma) for 2 min. The sample was placed onto the grid
or 2 min. Spotted grids were then stained with 30 ml of
2% uranyl acetate solution for 2 min. Excess stain was
emoved and grids were air dried. Specimens were then
xamined with a Zeiss EM 900 electron microscope
t 80 kV.
ytotoxic T lymphocyte assays
Eight to 10-week-old female BALB/c, C57BL/6, and
LA-A2.1Kb transgenic mice were immunized by intra-
muscular injection with 20 mg of polytope BPV1L1 VLPs
n PBS and subsequently boosted at day 21. Control mice
ere immunized with PBS, polytope VLPs denatured by
oiling at 100°C for 10 min, or wild-type VLPs. Mice were
acrificed on day 28, spleens were removed, and a
ingle cell suspension was held in complete RPMI 1640
edium supplemented with 10 U/ml rIL-2 (Sigma) andtimulated with peptide for 3 days. For HIV p18 CTL, the
ffectors were generated by restimulation with HIV p18eptide RIQRGPGRAFVTIGK (single letter AA code). For
PV16 E7 CTL, effectors were generated by restimula-
ion with HPV16 E7 CTL peptide RAHYNIVTF. For HIV
T-polymerase, effectors were generated by restimula-
ion with HIV RT-polymerase peptide VIYQYMDDL. For
IV nef CTL, effectors were generated by restimulation
ith HIV nef peptide PLTFGWCYKL. The predicted amino
cid sequence of the corresponding region of the poly-
ope is PLTFGWCFKL. The effectors were then used in
tandard 51Cr-release assays against peptide-sensitized
argets. Peptide-sensitized target cells were sensitized
ith 2 mg/ml peptide for 2 h at 37°C followed by two
ashes in medium. Effector cells and labeled target cells
ere plated into 96-well round-bottom plates at various
ffector/target ratios and incubated at 37°C, 5% CO2, for
h. A total of 25 ml of supernatant was collected to
Lumaplates from each well, dried at 42°C, and counted
with a gamma counter. The percentage of specific lysis
was calculated as specific lysis 5 (sample release 2
spontaneous release)/(maximum release 2 spontane-
ous release) 3 100. Maximum release was generated by
adding 100 ml of 10% SDS to 100 ml of target cells, and
pontaneous release was assayed from 100 ml of target
ells incubated with 100 ml of medium. Assays were
erformed in triplicate, and spontaneous 51Cr release
rom the various targets did not exceed 15%.
LISA assays for anti-VLP serum IgG
Measurement of total VLP-specific IgG in serum was
erformed in flat-bottom microtiter plates, as previously
escribed (Peng et al., 1998). Briefly, a rabbit anti-BPV1
ntiserum was used to coat the plates. After blocking
ith 5% milk/PBS, 50 ml VLPs at a concentration of 10
mg/ml was added to each well and incubated at 37°C for
90 min. Sera were tested by fourfold serial dilution in 5%
milk/PBS. Bound antibody was detected with horserad-
ish-peroxidase-conjugated sheep anti-mouse IgG at a
dilution of 1:1000, followed by incubation with OPD in the
presence of hydrogen peroxide. The reaction was
stopped with 3 N HCl and absorbance was measured at
450 nm.
Peptide ELISA
Microtiter plates (Dynatech) were coated overnight
with 50 ml of E7 antibody peptide (Fernando et al., 1998).
fter being blocked for 2 h at 37°C with 100 ml of 5% BSA,
0.05% Tween 20, in PBS, plates were washed three times
with PBS/0.05% Tween 20. A total of 50 ml of sera at
various dilutions was added for 1 h. Plates were washed
again and 50 ml of goat-anti-mouse IgG peroxidase con-
jugate was added at a 1:5000 dilution. After 1 h, plates
were washed before the addition of ABTS substrate
(0.2 mg/ml 2,29-azino-bis(3-ethylbenzthiazoline-6-sulfonic
acid) in 0.1 M Na–acetate–phosphate buffer [pH 4.2] with
4 ml of 30% H2O2 per 10 ml). Absorbance was measured
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381VLPs TO DELIVER MULTIPLE CYTOTOXIC T CELL EPITOPESafter 1 h at 490 nm in a Dynatech automated plate reader.
As a control, readings from wells coated with peptide
were compared to wells coated with PBS only.
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